Medicare Covers Obesity Drugs: A Health Revolution?

For decades, Medicare has covered the costly treatments for illnesses caused by obesity, such as heart disease and diabetes, while refusing to cover medications for obesity itself. This contradiction is beginning to be addressed through the Medicare GLP-1 Bridge demonstration program. Launched recently, this program offers eligible Medicare beneficiaries access to certain anti-obesity medicines for $50 per month.

The program is set to run through the end of 2027. It aims to provide valuable data on utilization, access, and spending, potentially influencing future coverage decisions. Clinical evidence for these GLP-1 medications is compelling, with trials showing substantial average weight loss and a reduced risk of cardiovascular events.

While some projections estimate significant federal deficit increases with broader coverage, other analyses suggest potential long-term savings for Medicare through reduced hospitalizations and chronic disease progression. The GLP-1 Bridge initiative allows for real-world evaluation of these competing economic and health outcome projections.